STERIS Beats on Q2, Lifts FY27 EPS Outlook to $11.35-$11.55
STE sits 27% above its 52-week low of $195.14 on elevated volume (2.0× avg).
Summary
STERIS posted fiscal Q2 revenue of $1.6 billion, up 9% as reported with 8% constant currency organic growth, and adjusted EPS of $2.94 versus $2.47 a year ago. Net income was $213.7 million, or $2.19 per diluted share. Life Sciences was the standout, with revenue up 18% to $170.6 million on 53% capital equipment growth, and management raised that segment's full-year organic growth outlook to 9-10% from 6-7%. The company lifted FY27 adjusted EPS guidance to $11.35-$11.55 from $11.10-$11.30, though about $0.18 of that comes from tariff refunds received year-to-date rather than operations. Offsets: AST organic growth outlook was trimmed to 6-7% from 7-8%, and a new targeted restructuring adds roughly $45 million in charges for only about $9 million in annualized savings. Management hosts a call November 5 at 9:00 am ET and will issue a revised outlook including the pending $2.1 billion Xodus Medical acquisition after closing.
At the time of this announcement, STE was trading at $247.91 on NYSE in the Life Sciences sector, with a market capitalization of approximately $24.2B. The 52-week trading range was $195.14 to $269.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.